GlaxoSmithKline’s (GSK) “Buy” Rating Reaffirmed at The Goldman Sachs Group
By Gomez in Business
Updated 3 years ago
The Goldman Sachs Group restated their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research note released on Thursday morning, Price Targets.com reports. The Goldman Sachs Group currently has a GBX 1,810 ($23.65) price target on the stock. Several other equities analysts also recently commented on the company. Credit...
